{'fraction_non_alphanumeric': 0.036044362292051754, 'fraction_numerical': 0.013863216266173753, 'mean_word_length': 5.811320754716981, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS.

Tuberculosis remains a growing threat of infectious diseases of twenty-first century. An attempt to find new antituberculosis agents was made especially to treat multidrug-resistant and extensively drug-resistant tuberculosis. One of the most promising drugs is bedaquiline - a new drug approved by Food and Drug Administration (FDA) and by the European Union countries. This compound is intended to treat multidrug-resistant pulmonary tuberculosis in adult patients in combination regimens in case of impossibility of using other drugs. This paper is also focused on some interesting molecules in treating multidrug-resistant tuberculosis which are currently tested in clinical studies: delamanid (dihydro-nitroimidazooxazole derivative, phase III), AZD5847 (oxazolidinone derivative, phase II), pretomanid (nitroimidazole derivative, phase III), sutezolid (oxazolidinone derivative, phase II) and SQ109 (ethambutol analogue, phase II) and some prospective molecules at the level of preclinical studies e.g., CPZEN-45, SQ609 and SQ641.